Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 25, 2020 06:30 ET | Source: Morphic Therapeutic

Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases

AbbVie to pay Morphic license fee of $20 million, with future potential milestones and royalties AbbVie to lead further development and commercialization WALTHAM, Mass., Aug. 25, 2020 (GLOBE...